CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8 enrolled
Drug / intervention
copper Cu 64-DOTA-trastuzumab +3 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01939275
NCT01939275N/ACompleted
CompareCT.gov

64Cu-DOTA-trastuzumab Positron Emission Tomography in Patients With Gastric Cancer

City of Hope Medical Center·interventional·Posted Sep 11, 2013·Updated Feb 28, 2025

In Brief

A clinical study evaluating copper Cu 64-DOTA-trastuzumab, positron emission tomography, and 2 other interventions for Adenocarcinoma of the Gastroesophageal Junction and 12 related conditions. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer. Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab PET/CT, may help doctors study the characteristics of tumors and choose the best treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IA Gastric Cancer, Stage IB Gastric Cancer, Stage IIA Gastric Cancer, Stage IIB Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 11, 2013
Enrollment StartNov 19, 2014
Primary CompletionMar 30, 2019
Study CompletionAug 5, 2024
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 12.8 years ago

Interventions

copper Cu 64-DOTA-trastuzumabradiation

Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

positron emission tomographydevice

Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

laboratory biomarker analysisother

Correlative studies

Computed Tomographyprocedure

Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan